Evidence map›Paper›PMID 38128044›Full record

ArticlePloS one2023

Distribution pattern, molecular transmission networks, and phylodynamic of hepatitis C virus in China.

Jingrong Ye, Yanming Sun, Jia Li, Xinli Lu, Minna Zheng, Lifeng Liu, Fengting Yu, Shufang He, Conghui Xu, Xianlong Ren and 7 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jingrong YeInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Yanming SunInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Jia LiInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Xinli LuInstitute for HIV/AIDS and STD Prevention and Control, Hebei CDC, Shijiazhuang, Hebei, China.
Minna ZhengInstitute for HIV/AIDS and STD Prevention and Control, Tianjin CDC, Hedong District, Tianjin, China.
Lifeng LiuCenter for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, Feng Tai District, Beijing, China.
Fengting YuClinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Chaoyang District, Beijing, China.
Shufang HeInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Conghui XuInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Xianlong RenInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Juan WangInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Jing ChenInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.
Yuhua RuanDivision of Virology and Immunology, State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, Changping District, Beijing, China.
Yi FengDivision of Virology and Immunology, State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, Changping District, Beijing, China.
Yiming ShaoDivision of Virology and Immunology, State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, Changping District, Beijing, China.
Hui XingDivision of Virology and Immunology, State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, Changping District, Beijing, China.
Hongyan LuInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Dong Chen District, Beijing, China.ORCID 0000-0002-3858-6858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In China, few molecular epidemiological data on hepatitis C virus (HCV) are available and all previous studies were limited by small sample sizes or specific population characteristics. Here, we report characterization of the epidemic history and transmission dynamics of HCV strains in China. We included HCV sequences of individuals belonging to three HCV surveillance programs: 1) patients diagnosed with HIV infection at the Beijing HIV laboratory network, most of whom were people who inject drugs and former paid blood donors, 2) men who have sex with men, and 3) the general population. We also used publicly available HCV sequences sampled in China in our study. In total, we obtained 1,603 Ns5b and 865 C/E2 sequences from 1,811 individuals. The most common HCV strains were subtypes 1b (29.1%), 3b (25.5%) and 3a (15.1%). In transmission network analysis, factors independently associated with clustering included the region (OR: 0.37, 95% CI: 0.19-0.71), infection subtype (OR: 0.23, 95% CI: 0.1-0.52), and sampling period (OR: 0.43, 95% CI: 0.27-0.68). The history of the major HCV subtypes was complex, which coincided with some important sociomedical events in China. Of note, five of eight HCV subtype (1a, 1b, 2a, 3a, and 3b), which constituted 81.8% HCV strains genotyped in our study, showed a tendency towards decline in the effective population size during the past decade until present, which is a good omen for the goal of eliminating HCV by 2030 in China.

Indexed as

Hepatitis CHIV InfectionsSexual and Gender MinoritiesChinaGenotypeHepacivirusHomosexuality, MaleHumansMalePhylogeny

Identifiers

PMID38128044
PMCPMC10734925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.